
-
Kremlin rejects Europe's 'ultimatums' for truce with Ukraine
-
Ireland rugby captain Doris ruled out for up to six months
-
Algerian attack survivor vows to be heard in court battle with award-winning author
-
Europa League glory could be 'turning point' for Spurs: Postecoglou
-
White S.Africans resettled in US did not face 'persecution': govt
-
Gaza faces 'critical risk of famine': UN report
-
Indian teams defuse bombs in Kashmir border areas
-
Kim Kardashian testifies in Paris multi-million-dollar robbery trial
-
Alexander-Arnold exit will not overshadow Liverpool title party: Van Dijk
-
Osaka knocked out of Italian Open as fans await Sinner
-
France condemns 'fake news' over Europe leaders' cocaine accusation
-
Indian PM Modi set to address nation after Pakistan truce
-
With Israel ties on the table, UAE offers Saudis an example
-
UK urges Putin to 'get serious about peace'
-
Leicester Tigers name Parling to replace Cheika as head coach
-
UK govt toughens immigration plans as hard-right gains
-
Markets rally after China, US slash tariffs
-
Leo XIV urges release of jailed journalists as Zelensky invites to Ukraine
-
Film legend Bardot backs Depardieu ahead of sexual assault verdict
-
Mbappe shows fallen Real Madrid new road to riches
-
Drones hit Ukraine as Zelensky awaits Putin reply on talks
-
Indian great Kohli follows Rohit in retiring from Test cricket
-
UK hosts European ministers for Ukraine talks amid ceasefire call
-
Copenhagen to offer giveaways to eco-friendly tourists
-
Ocalan: founder of the Kurdish militant PKK who authored its end
-
Kurdish militant PKK says disbanding, ending armed struggle
-
Under pressure, UK govt unveils flagship immigration plans
-
India great Virat Kohli retires from Test cricket
-
US, China agree to slash tariffs in trade war de-escalation
-
Markets rally after China and US slash tariffs for 90 days
-
India, Pakistan military to confer as ceasefire holds
-
Kurdish militant group PKK says disbanding, ending armed struggle
-
Virat Kohli: Indian batting great and hero to hundreds of millions
-
India great Virat Kohli announces retirement from Test cricket
-
Netanyahu vows further fighting despite planned US-Israeli hostage release
-
Salt of the earth: Pilot project helping reclaim Sri Lankan farms
-
UK towns harness nature to combat rising flood risk
-
Romania's far-right candidate clear favourite in presidential run-off
-
UK lab promises air-con revolution without polluting gases
-
Reel tensions: Trump film trade war looms over Cannes
-
Peru hopes local miracle gets recognition under new pope
-
Opening statements in Sean Combs trial expected Monday
-
Indian army reports 'first calm night' after Kashmir truce with Pakistan holds
-
As world heats up, UN cools itself the cool way: with water
-
Pacers push Cavs to brink in NBA playoffs, Thunder pull even with Nuggets
-
US, China to publish details of 'substantial' trade talks in Geneva
-
Asian markets rally after positive China-US trade talks
-
Indians buy 14 million ACs a year, and need many more
-
Election campaigning kicks off in South Korea
-
UK hosts European ministers for Ukraine talks after ceasefire ultimatum

Genflow Biosciences PLC Announces Holding(s) in Company
Please note that from 22 March 2021, the Standard TR-1 Form should be completed and submitted to the FCA via our Electronic Submission System (ESS) in relation to notifications of voting rights held in issuers whose shares are admitted to trading on UK regulated markets.
Holders of voting rights in issuers whose shares are admitted to trading on UK prescribed markets such as AIM market, can continue to use this form to send their notifications to those issuers. Alternatively, if they wish they can register on ESS to be able to notify to us, produce a TR-1 Form via ESS and submit the downloaded version to issuers with shares admitted to trading on prescribed markets.
More information on how to submit a TR-1 Form via ESS is availablehere
LONDON, UNITED KINGDOM / ACCESS Newswire / May 12, 2025 / TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Genflow Biosciences | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify) iii: | ||||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Dr Moayyed Al-Qurtas | |||||
City and country of registered office (if applicable) | ||||||
4. Full name of shareholder(s) (if different from 3.) v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reachedvi: | 09/05/2025 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 12/05/2025 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |||
Resulting situation on the date on which threshold was crossed or reached | 4.45% | 4.45% | ||||
Position of previous notification (if applicable) | ||||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
SUBTOTAL 8. A | |||||||||
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Physical or cash Settlementxii | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 | |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | X | |||
Full chain of controlled undertakings through which the voting rights and/or the | ||||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
10.In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional informationxvi | ||||
Place of completion | City of London |
Date of completion | 12/05/2025 |
Notes
iPlease note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link:https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter
iiFull name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.
iiiOther reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.
ivThis should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.
In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:
- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;
- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;
- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;
- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;
- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;
- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;
- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).
vApplicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).
viThe date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.
viiThe total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.
viiiIf the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.
ixIn case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.
xDate of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.
xiIf the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].
xiiIn case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).
xiiiIf the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.
xivThe full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only in this way will the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain by numbering each chain accordingly. Please see the below example:
Name of ultimate controlling person A (chain 1)
Name of controlled undertaking B
Name of controlled undertaking C
Name of ultimate controlling person A (chain 2)
Name of controlled undertaking B
Name of controlled undertaking D
Name of ultimate controlling person A (chain3)
Name of controlled undertaking E
Name of controlled undertaking F
xvThe names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.
xviExample: Correction of a previous notification.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
P.M.Smith--AMWN